Sumatriptan and naproxen sodium for the acute treatment of migraine

Headache

Volumn 45, Issue 8, 2005, Pages 983-991

  Smith, Timothy R ^a   Sunshine, Abraham ^b   Stark, Stuart R ^c   Littlefield, Diane E ^d   Spruill, Susan E ^d   Alexander, W James ^d  

^a Unity Health Research and Ryan Headache Center   (United States)

^b Analgesic Development Ltd   (United States)

^c Innovative Clinical Research Center   (United States)

^d POZEN Inc   (United States)

Author keywords

Acute treatment; Clinical trial; Migraine; Naproxen sodium; NSAIDs; Sumatriptan

Indexed keywords

NAPROXEN; NAPROXEN PLUS SUMATRIPTAN; PLACEBO; SUMATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN AGONIST;

ADULT; ARTICLE; CHEST TIGHTNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG TOLERABILITY; ENCAPSULATION; FATIGUE; FEMALE; HEADACHE; HUMAN; INCIDENCE; MALE; MIGRAINE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SOMNOLENCE; SYMPTOMATOLOGY; TABLET FORMULATION; TINNITUS; TREATMENT RESPONSE; XEROSTOMIA; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG POTENTIATION; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NAPROXEN; PROSPECTIVE STUDIES; SEROTONIN AGONISTS; SUMATRIPTAN; TINNITUS; TREATMENT OUTCOME;

EID: 18844436507     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.05178.x     Document Type: Article

References (21)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002;346:257-270.
2. Silberstein SD. Migraine. Lancet. 2004;363 (9406):381-391.
3. Matchar DB. Evidence-based guidelines for migraine headache: pharmacological management of acute attacks. Available at: http://www.aan.com /professionals/practice/pdfs/gl0087.pdf. Accessed on January 2004.
4. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754-762.
5. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech. 2001;53(3):167-178.
6. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55(1):19-26.
7. Bigal ME, Lipton RB, Krymchantowski AV. The medical management of migraine. Am J Ther. 2004;11(2):130-140.
8. Tfelf-Hansen P, McEwen J. Nonsteroidal antiinflammatory drugs in the acute treatment of migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 2nd ed. Philadelphia, PA: Lippincott-Raven; 2000:391-397.
9. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetyl salicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol. 1989;165(2-3):251-258.
10. Kaube H, Williamson D, Cumberbatch M, Hill RG. Hargreaves RJ. Cyclooxygenase (COX-1) inhibition with ketorolac blocks central trigeminal transmission but not CGRP-release from peripheral trigeminal sensory neurons. Cephalalgia. 2000;20(4):283. [abstract].
11. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000;58(2B):428-430.
12. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia. 2002;22(4):309-312.
13. Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol. 2004;4(1):10.
14. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
15. nded. Cephalalgia. 2004;24(suppl 1):9-160.
16. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325(5):316-321.
17. Segre EJ. Naproxen sodium (Anaprox): pharmacology, pharmacokinetics and drug interactions. J Reprod Med. 1980;25(suppl 4):222-225.
18. Moyer S. Pharmacokinetics of naproxen sodium. Cephalalgia. 1986;6(suppl 4):77-80.
19. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633-658.
20. Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci. 1998;6(2):99-104.
21. Fuseau E, Petricoul O, Sabin A, et al. Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. Clin Ther. 2001;23:242-251.